Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-3-17
pubmed:abstractText
A novel class of azetidinone acid-derived dual PPARalpha/gamma agonists has been synthesized for the treatment of diabetes and dyslipidemia. The preferred stereochemistry in this series for binding and functional agonist activity against both PPARalpha and PPARgamma receptors was shown to be 3S,4S. Synthesis, in vitro and in vivo activities of compounds in this series are described. A high-yielding method for N-arylation of azetidinone esters is also described.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1464-3405
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1939-44
pubmed:dateRevised
2008-10-28
pubmed:meshHeading
pubmed-meshheading:18291645-Administration, Oral, pubmed-meshheading:18291645-Animals, pubmed-meshheading:18291645-Azetidines, pubmed-meshheading:18291645-Biological Availability, pubmed-meshheading:18291645-Copper, pubmed-meshheading:18291645-Crystallography, X-Ray, pubmed-meshheading:18291645-Cytochrome P-450 Enzyme System, pubmed-meshheading:18291645-Diabetes Mellitus, Experimental, pubmed-meshheading:18291645-Dyslipidemias, pubmed-meshheading:18291645-Ether-A-Go-Go Potassium Channels, pubmed-meshheading:18291645-Glucose, pubmed-meshheading:18291645-Mice, pubmed-meshheading:18291645-Mice, Mutant Strains, pubmed-meshheading:18291645-Molecular Structure, pubmed-meshheading:18291645-PPAR alpha, pubmed-meshheading:18291645-PPAR gamma, pubmed-meshheading:18291645-Protein Conformation, pubmed-meshheading:18291645-Stereoisomerism, pubmed-meshheading:18291645-Structure-Activity Relationship, pubmed-meshheading:18291645-Triglycerides
pubmed:year
2008
pubmed:articleTitle
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
pubmed:affiliation
Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-5400, USA.
pubmed:publicationType
Journal Article